Animal-Friendly Affinity Reagents: Replacing the Needless in the Haystack
Owner/Developer: Trends in Biotechnology
The multibillion-dollar global antibody industry produces an indispensable resource but that is generated using millions of animals. Despite the irrefutable maturation and availability of animal-friendly affinity reagents (AFAs) employing naïve B lymphocyte or synthetic recombinant technologies expressed by phage display, animal immunisation is still authorised for antibody production. Remarkably, replacement opportunities have been overlooked, despite the enormous potential reduction in animal use. Directive 2010/63/EU requires that animals are not used where alternatives exist. To ensure its implementation, we have engaged in discussions with the EU Reference Laboratory for alternatives to animal testing (EURL ECVAM) and the Directorate General for Environment to carve out an EU-led replacement strategy. Measures must be imposed to avoid outsourcing, regulate commercial production, and ensure that antibody producers are fully supported.
|Channel:||Website - Social media - Professional online network|
|Audience:||Scientists - Industry - Researchers|
|User access:||Open access|
|Updating frequency:||July 20 - 2016|
|Relevance:||Replacement - Reduction - Refinement|
|Purpose:||Animal welfare - Method development - Documentation and information|
|Legislative framework:||Directive 2010/63/EU|
|Technology/Tools:||Alternative test methods (in vitro) - Animal testing (in vivo)|
Did you find what you were looking for?Yes, I found it! No, I did not!
Thanks for your feedback! Please note that we cannot respond unless you supply your email address.
What are you looking for?
Please give us your feedback so we can improve the information on the page. Thank you in advance for your help. Please add your email address if you would like a reply.Please contact us by email if you have any questions.